Literature DB >> 8152400

Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine.

L T Wu1, P Dicpinigaitis, H Bruckner, W Manger, S Averbuch.   

Abstract

Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) is an effective treatment regimen for malignant pheochromocytoma. There have not been any significant acute cardiovascular effects reported following CVD treatment. Among seven patients with malignant pheochromocytoma treated with CVD at our institution, two patients with labile hypertension developed hypertensive crisis following CVD treatment. The marked increase in blood pressure correlated with an increase in urinary excretion of catecholamine metabolites in one patient. Further hypertensive crises following subsequent CVD treatments were avoided by optimizing each patient's antiadrenergic therapy. Similar to the approach used preoperatively for patients with resectable pheochromocytoma, maximal antiadrenergic therapy is essential in preventing hypertensive crises in patients with malignant pheochromocytoma undergoing CVD treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8152400     DOI: 10.1002/mpo.2950220607

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  4 in total

1.  Clinical characteristics and outcomes of pheochromocytoma crisis: a literature review of 200 cases.

Authors:  Y Ando; Y Ono; A Sano; N Fujita; S Ono; Y Tanaka
Journal:  J Endocrinol Invest       Date:  2022-07-20       Impact factor: 5.467

2.  Complete surgical removal of multiple tumor lesions in malignant pheochromocytomas produces a good prognosis.

Authors:  Satoshi Nozaki; Taku Naiki; Yoshinobu Moritoki; Shuzo Hamamoto; Toshiki Etani; Keitaro Iida; Rei Unno; Atsushi Okada; Noriyasu Kawai; Takahiro Yasui
Journal:  IJU Case Rep       Date:  2019-03-27

Review 3.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 4.  Treatment of malignant pheochromocytoma.

Authors:  R Adjallé; P F Plouin; K Pacak; H Lehnert
Journal:  Horm Metab Res       Date:  2009-08-11       Impact factor: 2.936

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.